Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 5/20 | 0.51 |
| ▸ | THRA | P10827 | 1/20 | 0.51 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3843485 | 1.00 | THRB (0.51) | THRBTHRANR5A1TSHRTP53 | |
| SCHEMBL1626220 | 0.84 | TDP1 (0.48) | — | |
| SCHEMBL28544034 | 0.84 | THRB (0.38) | THRBTHRAPLA2G4B | |
| SCHEMBL30087260 | 0.84 | ALDH1A1 (0.56) | THRBTHRAL3MBTL1 | |
| SCHEMBL8749655 | 0.83 | MAOB (0.52) | THRBTHRANR5A1TSHRTP53 | |
| SCHEMBL317833 | 0.83 | MAOB (0.52) | THRBTHRANR5A1TSHRTP53 | |
| SCHEMBL6319246 | 0.82 | ERN1 (0.54) | TSHRTP53 | |
| SCHEMBL4943412 | 0.82 | NR5A1 (0.46) | NR5A1TSHRTP53PLA2G4B | |
| SCHEMBL7763936 | 0.82 | NR5A1 (0.58) | NR5A1TSHRTP53PLA2G4BL3MBTL1 | |
| SCHEMBL4942064 | 0.82 | NR5A1 (0.46) | NR5A1TSHRTP53PLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3504251-B1 | NETWORK POLYMERS AND METHODS OF MAKING AND USING SAME | UNIV COLORADO REGENTS (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12187851-B2 | Network polymers and methods of making and using same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-01-07 | — | — | US | disclosed |
| US-20230119934-A1 | NETWORK POLYMERS AND METHODS OF MAKING AND USING SAME | UNIV COLORADO REGENTS (US) | 2023-04-20 | — | — | US | disclosed |
| US-11535713-B2 | Network polymers and methods of making and using same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2022-12-27 | — | — | US | disclosed |
| US-20210292482-A1 | NETWORK POLYMERS AND METHODS OF MAKING AND USING SAME | THE REGENTS OF THE UNIV OF COLORADO A BODY CORPORTATE (US) | 2021-09-23 | — | — | US | disclosed |
| EP-3504251-A1 | NETWORK POLYMERS AND METHODS OF MAKING AND USING SAME | The Regents of the University of Colorado, a Body Corporate (US) | 2019-07-03 | — | — | EP | disclosed |
| WO-2018039331-A1 | NETWORK POLYMERS AND METHODS OF MAKING AND USING SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2018-03-01 | — | — | WO | disclosed |
| US-7479504-B2 | Edg receptor agonists | MERCK & CO., INC. (US) | 2009-01-20 | — | — | US | disclosed |
| US-7351725-B2 | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists | MERCK & CO., INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351725-B2 | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists | MERCK & CO., INC. (US) | 2008-04-01 | — | — | US | disclosed |
| EP-1470137-A4 | EDG RECEPTOR AGONISTS | MERCK & CO INC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20050070506-A1 | Selective s1p1/edg1 receptor agonists | DOHERTY GEORGE A (US) | 2005-03-31 | — | — | US | disclosed |
| US-20050033055-A1 | Edg receptor agonists | MERCK SHARP & DOHME CORP. | 2005-02-10 | — | — | US | disclosed |
| EP-1470137-A1 | EDG RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20040058894-A1 | Selective S1P1/Edg1 receptor agonists | DOHERTY GEORGE A (US) | 2004-03-25 | — | — | US | disclosed |
| WO-2003062252-A1 | EDG RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070506-A1 | Selective s1p1/edg1 receptor agonists | S1PR1, S1PR3, S1PR5 | THRB 1562/4885THRA 1209/4885NR5A1 265/4885 |
| US-20040058894-A1 | Selective S1P1/Edg1 receptor agonists | S1PR1, S1PR3, S1PR2 | THRB 1271/4885THRA 1032/4885NR5A1 275/4885 |
| US-20050033055-A1 | Edg receptor agonists | EDNRA, EDNRB, GPR65 | THRB 408/4885THRA 344/4885NR5A1 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.